FDA needs more information on Osteoport:
This article was originally published in Clinica
LifeQuest Medical says the US FDA requires additional information in order to complete its review of the Osteoport PMA application. Clarifications and further analysis of existing data, as well as additional patient trials, may be necessary for the intraosseous infusion device.
You may also be interested in...
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
The US FDA wants manufacturers and compounding facilities to test drug products for methanol in alcohol ingredients, and responds to reports of fatal methanol poisonings of consumers who ingested alcohol-based based hand sanitizers.